Melanoma Reagents | abinScience

Melanoma has become the paradigm for immune checkpoint therapy, with BRAF/MEK-targeted and PD-1/CTLA-4-based combination regimens transforming patient outcomes. abinScience provides antibodies, recombinant proteins, and assay kits spanning BRAF, MAPK pathway, melanocyte-lineage diagnostic markers (S100, gp100/PMEL, Melan-A), and the full spectrum of immune checkpoint targets. RUO

Key Biomarkers & Targets

BRAF

V600E/V600K

BRAF V600 mutations present in ~50% of cutaneous melanomas. Target of vemurafenib and dabrafenib. 79 antibodies for mutation-associated signaling studies.

Antibodies

PD-1 / PD-L1

CD279 / CD274

First cancer type where anti-PD-1 (nivolumab, pembrolizumab) achieved durable responses. 260+ combined antibodies, proteins, and biosimilars.

Antibodies • Proteins • Biosimilars

CTLA-4

CD152

Ipilimumab (anti-CTLA-4) was the first checkpoint inhibitor approved in melanoma. 144 products for combination immunotherapy studies.

Antibodies • Proteins • Biosimilars

LAG-3 / TIGIT / TIM-3

Next-Gen Checkpoints

Emerging immune checkpoints under active clinical investigation in melanoma (relatlimab + nivolumab). 125+ combined products.

Antibodies • Proteins • Biosimilars

gp100 / PMEL

Melanocyte Antigen

Melanoma-associated antigen; target of tebentafusp (bispecific gp100×CD3). 20 antibodies for tumor antigen detection and T-cell assay development.

Antibodies • Biosimilars

S100

S100B / S100A4

Classic IHC diagnostic marker for melanocytic lesions. Serum S100B used for monitoring metastatic disease progression. 41 products.

Antibodies • Proteins

Why Researchers Choose abinScience for Melanoma

MAPK Pathway Depth BRAF → MEK → ERK signaling cascade covered end-to-end. Antibodies for studying resistance mechanisms to BRAF/MEK inhibitor combinations.

Complete Checkpoint Portfolio PD-1, PD-L1, CTLA-4, LAG-3, TIGIT, TIM-3, IDO1 — the most comprehensive immune checkpoint reagent set for melanoma immuno-oncology research.

Melanocyte-Lineage Diagnostics S100, gp100/PMEL, Melan-A/MART-1, MITF, SOX10, tyrosinase — a full panel for melanoma diagnosis and differentiation from other malignancies.

Bispecific & TCR-T Reference gp100–peptide/HLA-A2 complex antibodies and tebentafusp biosimilar for next-generation bispecific and TCR-based therapy development.

Original Manufacturer Pricing Direct-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

BRAF/MEK resistance profiling: Use BRAF, MEK1/2, and phospho-ERK antibodies (WB, IHC) to characterize acquired resistance mechanisms in melanoma cell lines and PDX models.
Immune checkpoint combination screening: Evaluate PD-1 + CTLA-4, PD-1 + LAG-3, and other dual-blockade strategies with recombinant checkpoint proteins in reporter cell-based assays.
Melanoma vs. non-melanoma differential diagnosis: Apply our S100, SOX10, gp100, and Melan-A antibodies in IHC panels to distinguish melanoma from poorly differentiated carcinoma and other spindle-cell tumors.
Neoantigen & TCR-T development: Use our gp100/HLA-A2 complex reagents and IDO1 proteins for T-cell activation assays, antigen-specific killing, and tumor immune evasion studies.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

Do you carry BRAF V600E mutation-specific antibodies?

Our anti-BRAF antibodies detect total BRAF protein. For V600E-specific detection, we recommend combining our BRAF antibodies (WB) with mutation-specific recombinant proteins as positive controls in your assay.

Which checkpoint antibodies are best for melanoma TIL analysis?

For tumor-infiltrating lymphocyte characterization, we recommend our anti-PD-1, CTLA-4, LAG-3, TIGIT, and TIM-3 antibodies. These are available as unconjugated or can be custom-conjugated for flow cytometry panels.

What diagnostic IHC panel do you recommend for melanoma?

A standard melanoma IHC panel includes S100 (high sensitivity), SOX10 (nuclear marker), Melan-A/MART-1 (cytoplasmic), and HMB45/gp100 (specific for melanosomes). We offer antibodies for all four markers.

Do you have tebentafusp-related reagents?

Yes — we offer a research-grade tebentafusp biosimilar and anti-gp100/HLA-A2 complex antibodies for binding characterization, competitive assays, and T-cell redirection studies.

Can I get custom antibodies for novel melanoma neoantigens?

Yes — our parent company AtaGenix provides custom antibody development from immunogen design through monoclonal antibody production, including peptide-MHC complex-targeting antibodies for immuno-oncology.

Research Biosimilar (157)

Stable Cell Lines (1)

Mammalian Cells (186)

Spike glycoprotein E1 (2)

Spike glycoprotein (10)

gB/Envelope glycoprotein B (1)

CD274/PD-L1 & TGFBR2 (1)

CD279/PD-1 & CD152/CTLA4 (4)

CD279/PD-1 & CD274/PD-L1 (1)

B7-H1 / PD-L1 / CD274 & CD3E (1)

F/Fusion glycoprotein F0 (5)

Spike Protein (Trimer) (2)

VSIR/VISTA & CD274/PD-L1 (1)

VEGFA & B7-H1 / PD-L1 / CD274 (1)

gE/Envelope glycoprotein E (1)

CD223/LAG3 & CD152/CTLA4 (1)

CD274/PD-L1 & CD3E (1)

CD274/PD-L1 & SLT-Ia (1)

CD274/PD-L1/B7-H1 (5)

PD-L1 & TGF-Beta (1)

gD/Envelope glycoprotein D (1)

HLA-A2-peptide (TDQVPFSV) Complex (1)

CD274/PD-L1 & VEGFA (1)

CD19 & PD-L1 & CD3E & CD137 (1)

CD274/PD-L1 & CD47/MER6 (1)

CD274/PD-L1 & CD28 & CD152/CTLA4 (1)

CD47/MER6 & CD274/PD-L1 (2)

SARS-CoV-2 Neutralization Antibody (3)

CD47/MER6 & PDCD1 / PD-1 & CD137/4-1BB/TNFRSF9 (1)

RBD (Omicron/BA.4/BA.5) (1)

gC/Envelope glycoprotein C (1)

CD152/CTLA4 & CD279/PD-1 (1)

HLA-A2-peptide (ITDQVPFSV) Complex (4)

EGFR & CD3E & PD-L1 & 4-1BB (1)

CD366/TIM-3 & CD274/PD-L1 (1)

CD274/PD-L1 & CD279/PD-1 (1)

CD274/PD-L1 & CD134/OX40 (1)

CD366/TIM-3 & CD279/PD-1 (2)

RBD (Omicron/BA.5) (3)

M/Matrix protein (2)

gp100 peptide-HLA Complex (1)

Human β Amyloid (1-42) (1)

RBD (Delta Plus) (1)

Spike glycoprotein (RBD) (1)

HLA-A2-peptide (YLEPGPVT) Complex (4)

CD137/4-1BB & CD274/PD-L1 (3)

TRP-1 & CD47/MER6 (1)

CD274/PD-L1 & TGFBR2/TGFR-2 (1)

CD80/B7-1 & CD86/B7-2 (2)

NP/Nucleoprotein (3)

CD47/MER6 & CD274/PD-L1/B7-H1 (2)

Human β Amyloid (1-40) (1)

HLA-A2-peptide (KTWGQYWQV) Complex (2)

Calprotectin (S100A8/9) (3)

TRP-1 & CD134/OX40 (1)

Simlukafusp Alfa (1)

Fluorescein & CD274/PD-L1 (1)

FLT1/VEGFR1 & CD274/PD-L1 (1)

RBD (Omicron/JN.1) (1)

G/Major surface glycoprotein G (1)

GP/Envelope glycoprotein (4)

T-cell surface antigen T3/Leu-4 epsilon chain (1)

EPO/Erythropoietin (1)

Exenatide acetate (2)

CD137/4-1BB/TNFRSF9& CD274/PD-L1/B7-H1 (1)

CD274/PD-L1 & CD137/TNFRSF9 (1)

CD152/CTLA4 & CD274/PD-L1 (1)

CD47/MER6 & PDCD1 / PD-1 / CD279 (1)

CD366/HAVCR2/TIM-3 (4)

Spike glycoprotein E2 (2)

RBD (Omicron/KP.2) (1)

VASH2/Vasohibin-2 (1)

T-cell surface glycoprotein CD3 epsilon chain (1)

TIGIT & CD274/PD-L1 (1)

CD274/PD-L1 & CD28 (1)

CD152/CTLA4 & CD134/OX40 (1)

CD274/PD-L1 & CD152/CTLA4 (1)

CD137/4-1BB & CD274/PD-L1 & ROR1 & CD3 (1)

CD223/LAG3 & CD279/PD-1 (4)

Felis catus (Cat) (9)

Canis lupus familiaris (1)

Neosartorya fumigata (1)

Tupaia chinensis (12)

Mus musculus (Mouse) (7)

Canis lupus familiaris (Dog) (8)

Homo sapiens (Human) (7)

Bioactivity: FACS (153)

Functional assay (158)

in vivo PD-L1 blockade (3)

in vitro PD-L1 blockade (3)

Bioactivity: FACS (1)

Research in vivo (158)

Functional assay (6)

Bioactivity testing in progress (31)

Research in vivo (4)

in vivo CTLA-4 neutralization (2)

in vivo intra-tumoral regulatory T cell depletion (2)

in vivo blockade (2)

Tupaia chinensis (4)

Mesocricetus auratus (1)

Coturnix japonica (1)

Cynomolgus monkey (1)

Callithrix jacchus (1)

Monodelphis domestica (1)

Oryctolagus cuniculus (4)

B7-H1 / PD-L1 / CD274 (1)

Mus musculus (Mouse) (1)

Drosophila grimshawi (1)

Drosophila willistoni (1)

Neosartorya fumigata (1)

Homo sapiens (Human) (4)

Kirsten murine sarcoma virus (1)

Kryptolebias marmoratus (1)

Avian retrovirus IC10 (1)

Avian rous-associated virus type 1 (1)

Carassius auratus (1)

Armenian Hamster (5)

Compare（max 4） Delete

Recombinant Proteins

Antibodies

Assay Kits

Melanoma Research Reagents

Key Biomarkers & Targets

Why Researchers Choose abinScience for Melanoma

Common Research Applications

Documents & QC Data

FAQs

960 product results for "Melanoma"

Aldafermin ELISA Kit (DF862018)

Sample type

Sensitivity

Range

Anti-Tirzepatide (LY3298176) Human IgG ELISA Kit (AP899028)

Sample type

Sensitivity

Range

SARS-CoV-2 Surrogate Virus Neutralization Test Kit (JN.1) (AK565098)

Sample type

Sensitivity

Range

SARS-CoV-2 Surrogate Virus Neutralization Test Kit (KP.2) (AK565108)

Sample type

Sensitivity

Range

PEDV Spike glycoprotein (RBD) ELISA Kit (VK564018)

Sample type

Sensitivity

Range

PEDV NP/Nucleoprotein ELISA Kit (VK727018)

Sample type

Sensitivity

Range

Human EPO/Erythropoietin ELISA Kit (HF703018)

Sample type

Sensitivity

Range

Anti-Golimumab ELISA Kit (AF879068)

Sample type

Sensitivity

Range

Anti-Ustekinumab ELISA Kit (AB769018)

Sample type

Sensitivity

Range

Anti-Palivizumab ELISA Kit (AK421018)

Sample type

Range

Quick access

Contact Us